World Lung 2019 – Lilly celebrates a win with first Loxo asset
Impressive results in lung cancer with Eli Lilly’s Ret inhibitor set the stage for approval next year, but Blueprint is not far behind.
Deciphera hopes Invictus win will be just the beginning
Positive data should pave the way for ripretinib’s approval in fourth-line GIST, but investors are already eyeing a bigger opportunity.
Asco 2019 – tepotinib and capmatinib fight over a new lung cancer niche
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Deciphera nears its biggest test
The small-molecule oncology player zeroes in on its first commercial opportunity.
JP Morgan 2019 – Lilly fans the M&A flames with Loxo Oncology deal
Deal adds a marketed small molecule and three pipeline agents, although Lilly will share revenue from Vitrakvi and LOXO-195 with Bayer.
JP Morgan 2019 day one roundup – happy days are here again
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
American Thyroid Association – Ret competitors move to thyroid cancer
The relatively niche cancer setting provides an important battleground for the targeted kinase inhibitor specialists Blueprint Medicines and Loxo Oncology.
World Lung 2018 – Alunbrig squares up to Xalkori, but the field is getting crowded
Takeda's drug leads the charge of small-molecule tyrosine kinase inhibitors, some of which are very much holding their own against the onslaught of immuno-oncology.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.